SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

DIVIS GREG J

(Last)

(First)

(Middle)

2280 SCHUETZ ROAD

(Street)

ST. LOUIS

63146

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
KV PHARMACEUTICAL CO /DE/ [ KVA/KVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2013

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Class A Common Stock	09/16/2013		J		1,225⁽¹⁾	D	$0	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Option to Purchase	$28.6	09/16/2013		J			28,775⁽¹⁾	⁽²⁾	09/28/2017	Class A Common Stock	28,775	$0	0	D
Option to Purchase	$2.95	09/16/2013		J			70,000⁽¹⁾	⁽³⁾	01/13/2019	Class A Common Stock	70,000	$0	0	D
Option to Purchase	$1.52	09/16/2013		J			10,000⁽¹⁾	⁽⁴⁾	04/24/2010	Class A Common Stock	10,000	$0	0	D
Option to Purchase	$1.62	09/16/2013		J			50,000⁽¹⁾	⁽⁵⁾	09/07/2020	Class A Common Stock	50,000	$0	0	D
Option to Purchase	$1.49	09/16/2013		J			70,000⁽¹⁾	⁽⁶⁾	09/08/2021	Class A Common Stock	70,000	$0	0	D
Option to Purchase	$1.32	09/16/2013		J			100,000⁽¹⁾	⁽⁷⁾	03/28/2022	Class A Common Stock	100,000	$0	0	D

Explanation of Responses:

1. On September 16, 2013, the Sixth Amended Joint Chapter 11 Plan of Reorganization of KV Pharmaceutical Company (the "Company"), which was confirmed by the United States Bankruptcy Court for the Southern District of New York on August 28, 2013, was consummated. As a result, all issued and outstanding shares of the Companys Class A Common Stock, Class B Common Stock and 7% Cumulative Convertible Preferred Stock, and the warrants and options exercisable therefor, were cancelled and extinguished.

2. Options were to become exercisable as to 10% on date of grant and in 10% increments on each anniversary date thereafter.

3. The option was to vest in three installments: 33% on January 13, 2010, 33% on January 13, 2011 and 34% on January 13, 2012.

4. The option was to vest in two installments: 50% on December 31, 2009 and 50% on December 31, 2010.

5. The option was to vest with respect to 16,500 shares on September 7, 2013, 16,500 shares on September 7, 2014 and the remaining 17,000 shares on September 7, 2015.

6. The option was to vest in three equal installments beginning on September 8, 2012.

7. The option was to vest 33% on March 28, 2013, 33% on March 28, 2014 and 34% on March 28, 2015.

	Greg J. Divis	09/18/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.